Immunic Inc CEO Dr Daniel Vitt Discusses Q1 Achievements and Milestones
Immunic Inc CEO Dr Daniel Vitt discusses the company's first-quarter achievements and upcoming milestones in the development of therapies for chronic inflammatory and autoimmune diseases.
Immunic Inc's CEO discusses the company's achievements, fundraising efforts, and upcoming milestones in the development of therapies for chronic inflammatory and autoimmune diseases. The recent allowance of a fourth US patent for vidofludimus calcium enhances its intellectual property portfolio around MS treatments and ensures long-term commercial exclusivity.